Päivi J. Koskinen

Dr. Päivi J. Koskinen

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2004 in FEBS Letters
Verified
Journal Article
Closed access
TATeija L.T Aho
Teija L.T Aho
JSJouko Sandholm
Jouko Sandholm
KPKatriina J Peltola
Katriina J Peltola
HMHarri P Mankonen
Harri P Mankonen
MLMichael Lilly
Michael Lilly
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen

1 October 1998 in Molecular Cell
Verified
Journal Article
Closed access
JLJoel D Leverson
Joel D Leverson
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
FOFrank C Orrico
Frank C Orrico
EREeva-Marja Rainio
Eeva-Marja Rainio
KJKatriina J Jalkanen
Katriina J Jalkanen
Scott NessScott Ness
Scott Ness

15 May 2004 in Blood
Verified
Journal Article
Closed access
PDF file
KPKatriina J. Peltola
Katriina J. Peltola
KPKirsi Paukku
Kirsi Paukku
TATeija L. T. Aho
Teija L. T. Aho
MRMarja Ruuska
Marja Ruuska
OSOlli Silvennoinen
Olli Silvennoinen
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
Signal transducer and activator of transcription 5 (STAT5) plays a critical role in cytokine-induced survival of hematopoietic cells. One of the STAT5 target genes is pim-1, which encodes an oncogenic serine/threonine kinase. Here we demonstrate that Pim-1 inhibits STAT5-dependent transcription in cells responsive to interleukin-3, prolactin, or erythropoietin. Ectopic expression of Pim-1 in cytokine-dependent FDCP1 myeloid cells results in reduced tyrosine phosphorylation and DNA binding of STAT5, indicating that Pim-1 interferes already with the initial steps of STAT5 activation. However, the Pim-1 kinase does not directly phosphorylate or bind to STAT5. By contrast, Pim-1 interacts with suppressor of cytokine signaling 1 (SOCS1) and SOCS3 and potentiates their inhibitory effects on STAT5, most likely via phosphorylation-mediated stabilization of the SOCS proteins. Thus, both Pim and SOCS family proteins may be components of a negative feedback mechanism that allows STAT5 to attenuate its own activity.

15 February 2002 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EREeva-Marja Rainio
Eeva-Marja Rainio
JSJouko Sandholm
Jouko Sandholm
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
Pim-1 is an oncogenic serine/threonine kinase implicated in cytokine-induced signal transduction and in development of lymphoid malignancies. However, its precise function as well as physiological substrates have remained unknown. In this study we demonstrate that Pim-1 can physically interact with the NFATc1 transcription factor and phosphorylate it in vitro on several serine residues. In contrast to previously recognized NFATc kinases, wild-type Pim-1 enhances NFATc-dependent transactivation and IL-2 production in Jurkat T cells, while kinase-deficient Pim-1 mutants inhibit them in a dominant negative fashion. Our results reveal a novel, phosphorylation-dependent regulatory mechanism targeting NFATc1 through which Pim-1 acts as a downstream effector of Ras to facilitate IL-2-dependent proliferation and/or survival of lymphoid cells.

24 February 2000 in Oncogene
Verified
Journal Article
Open access
PDF file
AEAnne Eichmann
Anne Eichmann
LYLi Yuan
Li Yuan
CBChristiane Bréant
Christiane Bréant
KAKari Alitalo
Kari Alitalo
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
We have cloned a novel quail cDNA with strong homology to the pim family of proto-oncogenes. The deduced amino acid (aa) sequence of the cDNA, named qpim, is more closely related to Xenopus Pim and to the recently identified rat Pim-3 than to human or rodent Pim-1 or Pim-2. The protein encoded by the qpim cDNA can autophosphorylate itself and share substrates with murine Pim-1, suggesting functional redundancy to other Pim family serine/threonine kinases. We have compared the expression of qpim in avian embryos to mouse pim-1, -2 and -3 by in situ hybridization. qpim shows a highly dynamic expression pattern, particularly at early developmental stages. Surprisingly, its expression pattern is not identical to any of the murine pim genes, which show complementary and/or partially overlapping expression sites both in- and outside of the hematopoietic system. Altogether, our results suggest novel functions for Pim family kinases during embryonic development, in particular in epithelia and in the central nervous system.

19 October 2010 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
NSNiina M Santio
Niina M Santio
RVRiitta L Vahakoski
Riitta L Vahakoski
EREeva-Marja Rainio
Eeva-Marja Rainio
JSJouko A Sandholm
Jouko A Sandholm
SVSanna S Virtanen
Sanna S Virtanen
Päivi J. KoskinenPäivi J. Koskinen
Päivi J. Koskinen
Background: Pim family kinases are small constitutively active serine/threonine-specific kinases, elevated levels of which have been detected in human hematopoietic malignancies as well as in solid tumours. While we and others have previously shown that the oncogenic Pim kinases stimulate survival of hematopoietic cells, we now examined their putative role in regulating motility of adherent cancer cells. For this purpose, we inhibited Pim kinase activity using a small molecule compound, 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde (DHPCC-9), which we had recently identified as a potent and selective inhibitor for all Pim family members. Results: We now demonstrate that the Pim kinase inhibitor DHPCC-9 is very effective also in cell-based assays. DHPCC-9 impairs the anti-apoptotic effects of Pim-1 in cytokine-deprived myeloid cells and inhibits intracellular phosphorylation of Pim substrates such as Bad. Moreover, DHPCC-9 slows down migration and invasion of cancer cells derived from either prostate cancer or squamocellular carcinoma patients. Silencing of Pim expression reduces cell motility, while Pim overexpression enhances it, strongly suggesting that the observed effects of DHPCC-9 are dependent on Pim kinase activity. Interestingly, DHPCC-9 also abrogates NFATc-dependent migration of cancer cells, implying that NFATc factors mediate at least part of the pro-migratory effects of Pim kinases. Conclusions: Altogether, our data indicate that DHPCC-9 is not only a powerful tool to investigate physiological effects of the oncogenic Pim family kinases, but also an attractive molecule for drug development to inhibit invasiveness of Pim-overexpressing cancer cells.